Your session is about to expire
← Back to Search
HZN-1116 Dose 2 in Population 1 for Sjogren's Syndrome
Study Summary
This trial aims to determine how well and how safe HZN-1116 is for people with Sjogren's syndrome.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What is the current total number of participants being recruited for this clinical study?
"Affirmative, the information available on clinicaltrials.gov indicates that this medical study is actively seeking participants. This trial was initially posted on April 9th, 2024 and its most recent update occurred on April 26th, 2024. The research aims to recruit a total of 262 patients from three designated locations."
Is the enrollment process open for this medical study at present?
"Yes, information from clinicaltrials.gov indicates that this trial is currently enrolling participants. The trial was first posted on April 9th, 2024 and last updated on April 26th, 2024. It aims to recruit 262 patients across three designated sites."
Does this study allow participants who are older than 70 years of age?
"For enrollment in this clinical trial, individuals must be at least 18 years old but no older than 75."
What is the potential harm of administering HZN-1116 Dose 2 to individuals in Population 1?
"Based on our evaluation, the safety rating for HZN-1116 Dose 2 among Population 1 is scored at 2 by our team. This assessment is influenced by the absence of efficacy data despite some evidence supporting its safety in this Phase 2 trial."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Why did patients apply to this trial?
Share this study with friends
Copy Link
Messenger